Arktherapeutics Group, Plc

Calculating rank

USPTO Granted Patents = 4

% Expired Patents = 75.0

Forward Citations = 0

Loading Chart...

18 inventors (with patents filed for the assignee):

John Martin (2 out of 9 patents)

Hugh Edward Montgomery (2 out of 6 patents)

Jorge Daniel Erusalimsky (2 out of 6 patents)

4. Seppo Yla-Herttuala (1 out of 9 patents)

5. Basil Hartzoulakis (1 out of 11 patents)

6. Chris Chapman (1 out of 3 patents)

7. Haiyan Jia (1 out of 3 patents)

8. Ian Zachary (1 out of 4 patents)

9. Michelle Tickner (1 out of 2 patents)

10. Lili Cheng (1 out of 2 patents)

11. Katie Ellard (1 out of 2 patents)

12. Ashley Jarvis (1 out of 3 patents)

13. Rosemary Lynch (1 out of 2 patents)

14. Jamie Nally (1 out of 2 patents)

15. Mark Stewart (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 8188039 - VEGF-D mutants and their use (2012-05-29),

2. 8158789 - Arginine derivatives with NP-I antagonistic activity (2012-04-17),

3. 8003679 - Use of inhibitors of the renin-angiotensin system (2011-08-23),

4. 7998953 - Use of inhibitors of the renin-angiotensin system (2011-08-16),

Company Overview

Arktherapeutics Group, Plc is a biopharmaceutical company focused on developing innovative gene therapies and biologics to treat a range of diseases. With a strong pipeline of products in development, Arktherapeutics is committed to advancing medical science and improving patient outcomes through cutting-edge research and development efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

4 Patents

#658 in London

#3,877 in United Kingdom

London, United Kingdom